LLY•benzinga•November 18, 2024 at 07:52 PM

Lilly's Muvalaplin Reduces Lipoprotein(a) Levels By Up To 85% In High-Risk Cardiovascular Patients In Phase 2 Study; Results Published In JAMA And Presented At AHA 2024 Scientific Sessions

No summary available.

Read the full article from the original source for complete details and context.

Article published on November 18, 2024 by benzinga